An increase in cytosolic free calcium (Ca;) has been shown to occur early during ischemia in perfused rat, ferret, and rabbit hearts. It has been proposed that this increase in Cal may occur as a result of exchange of Nai for Ca., which occurs as a result of an increase in Na; arising from exchange of Na0 for H+;. The latter exchange is stimulated by the intracellular acidification that occurs during ischemia. To test this hypothesis, we examined Ca;, Na;, ATP, and pH; during ischemia in rats in the presence and absence of 1 mM amiloride, a Na-H exchange inhibitor. Ca; was measured using '9F nuclear magnetic resonance (NMR) of 1,2-bis(2-amino-5-fluorophenoxy)ethane-N, N, N', N'-tetra-acetic acid (5F-BAPTA) -loaded rat hearts. Na; was measured using 23Na NMR, and the shift reagent 1, 4, 7, 10-tetraazacyclododecane-N, N', N", N"'-tetramethylenephosphonate (Tm[DOTPI 5) was used to separate Nai and Na0. ATP and pH were determined from 31P NMR measurements. During 20 minutes of ischemia, amiloride did not significantly alter the ATP decline but did significantly attenuate the rise in Na; and Cai. After 20 minutes of ischemia, time-averaged Caj was 1.0±0.2 ,uM (mean+SEM) in amiloride-treated hearts compared with 23±0.9 p,M in nontreated hearts. After 20 minutes of ischemia, Nai in the untreated heart was threefold greater than control, whereas in the amiloride-treated heart, Nai was not significantly different from control. These data are consistent with the involvement of Na-Ca exchange in the rise in Caj during ischemia. In addition, recovery of contractile function during reperfusion after 20 minutes of ischemia was significantly better in amiloride-treated hearts (71±10%) than in nontreated hearts (24±13%). These data are consistent with the hypothesis suggesting that the elevation in Ca; during ischemia may contribute to postischemic contractile dysfunction. (Circulation Research 1991;68:1250-1258 An increase in cytosolic free calcium (Cai) has been shown to occur during early ischemia or metabolic inhibition in perfused rat, rabbit, and ferret hearts.1-6 However, the transport processes responsible for the rise in Caj are still unresolved. The rise in Caj observed during ischemia may indicate influx of calcium from the extracellular space and/or release of calcium from intracellular stores. The rise in Caj during ischemia7 or metabolic inhibition4 is largely attenuated by lowering Ca0, thus demonstrating the importance of calcium influx. The three transporters for calcium in the plasma membrane include calcium channels, Ca-ATPase, and the Na-Ca exchanger. Although there is evidence4'8 that during ischemia calcium channel blockade slows the
rise in Cai, it is difficult to separate the effects of calcium channel blockade during ischemia from the ATP-sparing cardioplegic effect of the calcium channel blockers. Furthermore, calcium entry through calcium channels cannot be the sole mechanism responsible for increased Caj during ischemia, because an increase in Caj was eventually observed in the presence of complete calcium channel blockade. 8 Little is known about alterations in calcium efflux via Ca-ATPase during ischemia; however, it is clear that, if ATP falls below its Ki, this enzyme will be inhibited. Na-Ca exchange has also been postulated as a possible source for the increased Caj observed during ischemia.
Interactions between pHi, Cai, and Nai, which occur through Na-H and Na-Ca exchange, have recently been demonstrated.9'10 These studies have led to the hypothesis that Na-H exchange may be important in causing the increase in Caj during ischemia. An increase in Nai has been observed after approximately 10 minutes of ischemia. [11] [12] [13] This increase in Nai appears to be due at least in part to Na-H exchange, since the Nai accumulation correlates with H' load and not with ATP content. '4 Amiloride, an inhibitor of Na-H exchange, given before ischemia15,16 or during hypoxia,17 improved recovery of function during reperfusion/reoxygenation. Anderson et a118 showed that ethylisopropylamiloride, a Na-H exchange inhibitor, blocks the rise in Nai that otherwise occurs during hypoxia in the presence of Na-K pump inhibition. The time course of the increase in Nai1l-13 is similar to the time course for the rise in Cai, suggesting that the increase in Nai could stimulate Na-Ca exchange and thus produce an increase in Ca, during ischemia.
Evidence that Na-Ca exchange secondary to increased Nai could be a factor in the rise in Caj under hypoxic conditions is provided by the study of Anderson et al, 18 which showed a rapid rise in Caj parallel to the rise in Nai observed during hypoxia with glucose present and the Na-K pump inhibited. Both the rise in Nai and the rise in Caj could be blocked with ethylisopropylamiloride. In the pump-inhibited heart exposed to hypoxia with exogenous glucose, H+ generation is maintained at a high rate, H', accumulation is minimal because of continuous perfusion, and Na-K pump inhibition prevents sodium extrusion by the Na-K pump. These are ideal conditions to observe an increase in Nai and net calcium influx due to Na-Ca exchange. During ischemia, there is limited glucose to generate lactic acid, and the Na-K pump appears to remain at least partially active. 19 Thus, it remains to be established whether drugs such as amiloride can block the rise in Nai and Caj observed during ischemia. In this manuscript we show that amiloride (1 mM) significantly attenuates the increase in Nai and Caj observed during ischemia. In addition, unlike the case for calcium channel blockade, ATP falls with a similar time course in the presence and absence of amiloride; thus, we can dissociate the increase in Caj from the decrease in ATP. We further report that the presence of amiloride during ischemia allows better recovery of contractile function during reflow after 20 minutes of ischemia. Amiloride, however, does not significantly alter the time to the onset of lethal injury as measured by the release of the intracellular enzyme creatine phosphokinase.
Materials and Methods
Adult male Sprague-Dawley rats (Charles River Laboratories, Inc., Wilmington, Mass.) weighing 200-300 g were anesthetized with pentobarbital. The heart was excised, and the aorta was cannulated. Retrograde perfusion was started from a reservoir 90 cm above the aortic cannula. The nonrecirculating perfusate was a Krebs-Henseleit buffer containing (mM) NaCl 120, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.25, NaHCO3 25, and glucose 10. The buffer was continuously aerated with humidified 95% 02-5% CO2 and was maintained at 37°C. After 15 minutes of control perfusion, loading with 300-500 ml of 5 4M of the acetoxymethyl ester of 1,2-bis(2-amino-5-fluorophenoxy)ethane-N,N,N',N'-tetraacetic acid (SF-BAPTA) was started. With typical flow rates of 10 ml/min, loading took 30-50 minutes.
After loading with 5F-BAPTA, hearts were perfused with phosphate-free Krebs-Henseleit buffer (pH adjusted to 7.4 by adding HCl) for -30 minutes, during which time the magnet was shimmed and several preischemic spectra were acquired. Phosphate-free buffer allows us to unambiguously assign the inorganic phosphate peak to the intracellular space as required for measuring pHi. The heart was placed in a standard 20-mm nuclear magnetic resonance (NMR) tube with the apex of the heart -1 cm from the bottom of the tube. The perfusate was evacuated by a variable speed Masterflex peristaltic pump (Cole-Parmer Instrument Co., Chicago) connected to polyethylene tubing that extended to the bottom of the tube; thus, the heart was not bathed in perfusate. The hearts were divided into two experimental groups. One group was perfused with phosphate-free Krebs-Henseleit buffer containing 1 mM amiloride for 5-10 minutes before ischemia, and the second group was perfused with the same buffer but did not receive amiloride. After ischemia, both groups were reperfused with phosphate-free Krebs-Henseleit buffer. In each experimental group, some hearts were evaluated by 19F NMR, some by 31p NMR, some by 23Na NMR, and some were perfused outside the magnet for measurement of enzyme release. Measurements of contractility were made in all experiments (both inside and outside the magnet). In the no-treatment group, five hearts were studied by 19F NMR, three hearts were studied by 31P NMR, three hearts were studied by 23Na NMR, and 19 hearts were studied outside the magnet. In the amiloride-treated group, five hearts were studied by 19F NMR, three hearts were studied by 31P NMR, three hearts were studied by 23Na NMR, and 23 hearts were studied outside the magnet.
For assessment of contractile function, a latex balloon on the tip of a polyethylene catheter was inserted through the left atrium into the left ventricle. The catheter was connected to a Statham P23d pressure transducer (Gould, Cleveland, Ohio) that was outside the magnet at the same height as the heart. The balloon was inflated to give an enddiastolic pressure of 5-10 cm H20. Initially, all hearts developed at least 100 cm H2O peak systolic pressure at an end-diastolic pressure of .10 cm H20. 5F-BAPTA loading has been shown previously to buffer calcium transients and thereby decrease peak systolic pressure to -25 cm H20 at an end-diastolic pressure of 10 cm H20.1 Hearts were not paced. Spontaneous beating rates were -250 beats/min. In 5F-BAPTAloaded hearts, this rate was maintained during the first 2 minutes of ischemia, after which time, detectable contractile activity ceased.
These studies were performed on an NT 360 wide-bore NMR spectrometer (Nicolet Instrument Corp., Fremont, Calif.) with the variable temperature probe at 37°C. For the 19F studies, we used a 20-mm 19F probe tuned to 339.7 MHz (Doty Scien-tific, Inc., Columbia, S.C.). We used a 20-mm broadband probe (Nicolet Instrument) tuned to 146.1 MHz for the 31P NMR studies and to 95.5 MHz for the 23Na NMR studies. The sample was shimmed on the water signal from the heart, and we routinely obtained a (nonspinning) line width at half height of -0.25 ppm. For the 19F NMR studies, we used a 400 pulse angle, a ±5-kHz spectral width, a 205-msec recycle time, and 4,000 data points. These pulsing conditions approximately correspond to the Ernst angle for the fluorine resonance of 5F-BAPTA. A 700 pulse angle, a 1-second delay, a +5-kHz spectral width, and 4,000 data points were used for the 31P NMR studies. These parameters for 31P were chosen so we could measure changes with a 2.5-5-minute time resolution. With these pulsing parameters, we are overpulsing the resonances; to obtain a true concentration, we must apply correction factors that are dependent on the spin-lattice ralaxation (T1)20-22 values and our pulsing conditions. Creatine phosphate, ATP, and inorganic phosphate must be multiplied by 1.94, 1.18, and 1.73, respectively. For the 23Na NMR studies, we used 1,000 data points, a 750 pulse angle, a ±2,400-Hz spectral width, and a 106-msec recycle time.
As shown previously,2324 calcium binding to 5F-BAPTA has slow exchange kinetics; thus, Ca, is related to the observed resonance intensities by
where the Kd value for 5F-BAPTA is 700 nM at 37°C23 and [Ca-5F-BAPTA] and [5F-BAPTA] are proportional to the area under their respective resonance peaks. Since this measurement requires the comparison of resonance intensities, it is necessary to work under conditions of nonsaturation of the resonances or, alternatively, under conditions of equal saturation. Fortunately, 5F-BAPTA and Ca-SF-BAPTA have nearly identical spin lattice relaxation times,24 so that the intensity ratio of free to calciumcomplexed 5F-BAPTA is essentially independent of the rate of pulsing. Recent studies by Marban et a125 show that in the perfused heart 5F-BAPTA is not significantly compartmentalized into mitochondria or endothelial cells.
The concentration of intracellular indicator was determined at the end of the experiment by drying the heart to a constant weight and homogenizing with a Polytron (Brinkmann Instruments, Inc., Westbury, N.Y.) in 150 mM KCl, with excess EGTA, buffered with Tris-MOPS to pH 7.1. 19F NMR studies were carried out on the homogenate to which a known concentration of 6-fluorotryptophan was added. The resonance intensity of 5F-BAPTA was then compared with that of the 6-fluorotryptophan, taking into account the differences in T1 and the number of fluorine nuclei.
Creatine phosphokinase activity in the perfusate was assayed spectrophotometrically.26 pH was measured from the shift between intracellular inorganic phosphate and creatine phosphate as described.27 ATP expressed as percent of control was determined by measuring the area under the fl-phosphate resonance of ATP. In the 23Na spectra, Nai was distinguished from Na0 by using an extracellular shift reagent, 1,4,7,10-tetraazacyclododecane-N,N',N",N'tetramethylenephosphonate (Tm[DOTP] 5), which was synthesized as described by Sherry et a128 and Buster et al. 29 The sodium free-induction decay was multiplied by a combined exponential and gaussian function of 10 Hz. The area under the Nai resonance was normalized by comparison with an external standard and expressed as percent of control.
Statistics
Values are expressed as mean+SEM. The difference between two means was tested by an unpaired two-tailed t test. A value of p<0.05 was considered significant. Figure 1 shows a series of 19F NMR spectra obtained from a 5F-BAPTA-loaded perfused rat heart before and during global ischemia in the absence (panel A) and presence (panel B) of 1 mM amiloride, an inhibitor of Na-H exchange. As described in "Materials and Methods," Caj is obtained from the 19F NMR spectrum by multiplying the Kd by the ratio of the areas under the Ca-5F-BAPTA and uncomplexed 5F-BAPTA resonances. Each 19F spectrum is an average of 3,000 accumulations, and since we are not gating to the cardiac cycle, these spectra represent time-averaged values for Cai; in the beating heart, this value is 579±53 nM.
Results
The 31P NMR experiments were performed on hearts loaded with 5F-BAPTA and followed the same protocol as for the 19F NMR experiments. Figure 2 shows a series of 31P NMR spectra before and during global ischemia in the absence (panel A) and presence (panel B) of 1 mM amiloride. pHi was determined from the shift difference between creatine phosphate (peak b) and inorganic phosphate (peak a), as described previously. 27 Since the hearts were perfused with a phosphate-free Krebs-Henseleit buffer, the inorganic phosphate signal is derived from intracellular inorganic phosphate. ATP levels (expressed as percent of control) were also obtained from the 31P NMR spectra by integrating the area under the f3-ATP resonance peak. The 31P NMR pulsing parameters were set to optimize time resolution and to show relative changes in ATP content.
Thus, we are overpulsing some of the phosphate resonances, and corrections must be made to obtain true metabolite concentrations (see "Materials and Methods").
The 23Na experiments were also performed on hearts loaded with SF-BAPTA and followed the same protocol, except that 5 mM Tm(DOTP)-5 was added to separate Nai from Na0. Malloy et al12 have shown previously that, if sufficient calcium is present, Tm(DOTP) -does not alter cardiac function. Figure  3 shows`3Na spectra before and during global ischemia in the absence (panel A) and presence (panel B) of 1 mM amiloride. Figure 4 summarizes the time course of changes in Cat, Nai, pHi, and ATP in ischemic perfused rat hearts in the presence and absence of 1 mM amiloride. A comparison of Caj in the presence and absence of amiloride shows that significant differences (p<0.05) are apparent by 10 Nai is significantly different with and without amiloride at all times between 10 and 20 minutes of ischemia. pHi levels during ischemia are not significantly altered by the presence of amiloride, and the decline in ATP is not significantly different at any time in the presence or absence of amiloride. Figure 5 shows the relation between Caj and ATP during ischemia with and without amiloride. As ATP falls below -50% of the control level, Caj is significantly higher in the absence of amiloride. The relation between pH and ATP is not altered by the presence of amiloride (data not shown). The presence of amiloride slightly delays the increase in resting tension that occurs during ischemia ( Figure 6 ). The tl12 to reach peak contracture pressures occurred at -8 minutes in the absence of amiloride compared with -10 minutes in the presence of amiloride. Recovery of contractile activity during reperfusion after 20 minutes of ischemia was significantly improved in the amiloride-treated heart. preischemic pressure compared with 24±13% for untreated hearts. As shown in Figure 7 , however, amiloride did not significantly alter the relation between the duration of ischemia and enzyme release during reperfusion. Although amiloride is an order of magnitude more potent at inhibiting Na-H exchange than Na-Ca exchange,30 we were still concerned about the specificity of amiloride at this high concentration (chosen to be comparable with earlier studies16). Therefore, we tested the ability of 5-N,N-dimethylamiloride (DMA), a compound 100 times more selective for Na-H than for Na-Ca exchange,30 to inhibit the ischemia-induced rise in Cai. As shown in Figure 8 , DMA at 50 uM (Ki for Na-H exchange=4.2 ,uM, Ki for Na-Ca exchange=550 gM30) was as effective as 1 mM amiloride in delaying the rise in Cai.
Amiloride-treated hearts recovered 71 ± 10% of

Discussion
Although recent studies have shown that Caj increases during ischemia, the source of the rise in Caj as well as the importance of a rise in Caj in the development of cell injury are still debated. Designing effective strategies to block the rise in Ca, requires knowledge of its source. It has been suggest-ed18 that the increase in H' that occurs during hypoxia or ischemia would lead to an increase in Nai via Na-H exchange. It is further hypothesized that the increase in Nai would lead to an increase in Caj via Na-Ca exchange. To test this hypothesis, we examined the ability of amiloride, an inhibitor of Na-H exchange, to attenuate the ischemia-induced increase in Nai and Cai. As seen in Figure 4 , amiloride delays both the rise in Nai and Cat, consistent with this hypothesis. The 139% increase in Nai after 15 minutes of ischemia reported in this study is similar to the 133% increase in Nai reported by Malloy et a112 after 15 minutes of ischemia.
Amiloride also blocks the increase in Nai that occurs during 25 minutes of ischemia. If ischemia is extended beyond that time, Nai rises even in the presence of amiloride (data not shown). This suggests that Na-H exchange is a significant entry pathway for sodium during the initial 25 minutes of ischemia. Amiloride delays the increase in Caj during ischemia, but it does not block it. By 25 minutes of ischemia in the presence of amiloride, Caj is not significantly different from Caj after 20 minutes of ischemia in the absence of amiloride. The ability of amiloride to significantly delay the rise in Caj during ischemia would suggest that coupled Na-H and Na-Ca exchange is a significant early entry pathway for calcium during ischemia. This is the first direct demonstration of the ability of amiloride to attenuate the increase in Nai and Caj during ischemia.
If Nai increases during ischemia and if subsequent
Na-Ca exchange is the sole mechanism responsible for the increase in Cai, then one might expect that an increase in Nai must precede the increase in Cai.
Examination of Figure 4 shows that this is not the case. The increase in Ca1 precedes the increase in Nai. In the absence of amiloride, Ca1 is significantly above control by 10 minutes of ischemia, whereas Na1 does not significantly rise above control until -15 minutes of ischemia. Similarly, in the presence of amiloride, Ca1 starts to rise by 20 minutes of ischemia, a time at which Nai has not yet significantly increased. Possible explanations for this discrepancy include the following: 1) There are other mechanisms that contribute to the increase in Cai, for example, entry through calcium channels or release from intracellular stores. 2) It is possible that an initial increase in net sodium influx could be masked by rapid Na-Ca exchange. Support for this conclusion comes from the observation that during Na-K pump inhibition, Na-Ca exchange occurs and significantly attenuates the increase in Nai.31'32 Amiloride at high concentrations can also directly inhibit Na-Ca exchange. 33 Although we cannot rule out some direct inhibition of Na-Ca exchange by amiloride, it would not alter our basic conclusion that Na-Ca exchange is a significant early calcium entry pathway during ischemia. Furthermore, inhibition of Na-Ca exchange could not account for both an increase in Nai and Cai. In fact, inhibition of Na-Ca exchange should lead to higher Nai levels during ischemia, which is the opposite of what was observed. Further support for the hypothesis that an inhibition of Na-H exchange delays the ischemia-induced increase in Ca1 is taken from Figure 8 , where it is shown that DMA, at a concentration an order of magnitude below the Ki for Na-Ca exchange,30 delays the increase in Ca1 similar to that observed with amiloride.
Since amiloride inhibits Na-H exchange,34 protons generated during ischemia cannot be extruded via Na-H exchange. Therefore, it was somewhat surprising that there was not a greater decline in pHi during ischemia in the presence of amiloride. The regulation of pHi, however, is influenced by many factors.
Interactions between pH and calcium are well documented; increasing Ca, is known to decrease pH1 secondarily.3536 After 20 minutes of ischemia, the rise in Ca, is less in the presence of amiloride; thus, with amiloride there would be less of a decrease in pHi due to this mechanism. In addition, there are other mechanisms that regulate pHi,37,38 and presumably they can compensate for the absence of Na-H exchange. During ischemia, pHi falls from 7.1 to 6.4;
this is an increase in [H'] of 0.32 ,uM, clearly not sufficient to bring about a 10 mM increase in Nai via Na-H exchange. It is not the [H'], however, that is important; it is the H' generated during ischemia. Data in the literature39,40 demonstrate that lactate production during 10-20 minutes of ischemia is 118-166 ,mol/g dry tissue wt. Assuming 2.5 ml intracellular water/g dry wt, this corresponds to [H'] of 47-66 mM, more than sufficient H+ to account for the corresponding increase in Na+ (-10-30 mM). This large amount of lactate does not cause a corresponding decrease in pH1, because some of the lactate (or H+) is transported out of the cell and Hi is highly buffered.
Since low pH has been shown to inhibit Na-Ca exchange,41 it has been suggested that Na-Ca exchange would be inhibited during ischemia, when pH is decreased. However, the relation between pH and Na-Ca exchange activity is strongly affected by sodium. As shown by Philipson et al,41 the inhibition of Na-Ca exchange by low pH is manifest only at low sodium. Since Nai is elevated during ischemia,11-13 it can compete with H+ and offset the inhibitory effect of the low pH. Further support for Na-Ca exchange under conditions of low pH is taken from Lazdunski et al (see Table 2 of Reference 9), who show that recovery from acidosis (pH 6.6) in Na,K-ATPaseinhibited cells causes a fivefold increase in 45Ca uptake. These data suggest that even with a decrease in pHi, an elevation in Nai can stimulate Na-Ca exchange in intact cells.
Since the data in this paper show that amiloride delays the ischemia-induced rise in Ca1 but not the decline in ATP or pHi, we can now evaluate the effect of a decline in ATP and pHi, independent of an increase in Ca1. Similar to what has been shown by absence (open squares) of amiloride. Resting tension was Ca, and A TP levels correspond to data in Figure 3 Although the presence of amiloride during ischemia improves contractile activity when hearts are reperfused after 20 minutes of ischemia, the presence of amiloride during ischemia does not significantly alter enzyme release when hearts are reperfused after 60, 90, or 150 minutes of ischemia. This result is different from the observation of Karmazyn,15 who showed that creatine phosphokinase release during reperfusion after 30 and 60 minutes of low-flow ischemia is lowered by amiloride pretreatment. This conflicting finding may be due to a difference between total ischemia and low-flow ischemia; the continuous infusion of amiloride may also be a factor. Substantial enzyme release during reflow does not occur unless a heart has been ischemic for 60-90 minutes or longer. Thus, during ischemia there is a very long lag period between the increase in Caj and plasma membrane disruption, which allows enzyme release to occur. It has been suggested42 that the increase in Caj may activate proteases or phospholipases, which in turn may lead to structural membrane damage; thus, it is not unreasonable that there is a significant time lag between the increase in Ca, and plasma membrane disruption. The observation that amiloride pretreatment does not significantly alter the time course of ischemia-induced enzyme release could have several explanations. First, increased Caj may not be the proximate cause for the plasma membrane damage that leads to enzyme release.
Second, increased Caj may be necessary but not sufficient for plasma membrane disruption; modifications to the cell, perhaps induced by ATP depletion, may be required before increased Ca, can produce lethal plasma membrane damage. Since amiloride does not significantly delay ATP depletion and does not prevent an eventual rise in Cai, amiloride may not alter the time course of lethal injury. Third, increased Caj may be the most important factor in lethal injury, but the 5-10-minute delay in the rise in Caj with amiloride may be too small to detect when there is considerable biological variability in the time course of lethal ischemic injury. Fourth, amiloride may be degraded during the long ischemic interval required to observe enzyme release. In summary, the data herein show directly for the first time that amiloride does lessen the rise in Caj and Nai during ischemia. We also find, in agreement with the work of others,1516 that the presence of amiloride during ischemia allows improved recovery of contractile function during reflow. In addition, since ATP and pHi are not altered by the presence of amiloride, whereas the rise in Ca, (and Nai) is significantly altered, an association can now be made between the level of Caj during ischemia and the recovery of contractile function during reflow. This is consistent with the hypothesis that an elevation in Caj is involved in "stunning."43 Finally, these data suggest that amiloride may be a useful addition to cardioplegia solutions.
